Normocomplementaemic urticarial vasculitis: effective treatment with omalizumab.

Marianne de BritoGisela HuebnerDedeeF MurrellPeter BullpittKarin Hartmann

Published in: Clinical and translational allergy (2018)

We report two patients with normocomplementaemic urticarial vasculitis with impressive response to omalizumab. This contrasts recent reports on hypocomplementaemic urticarial vasculitis syndrome, highlighting the need for clinical trials of omalizumab in normocomplementaemic urticarial vasculitis.

Keyphrases

clinical trial
emergency department
randomized controlled trial
adverse drug
smoking cessation
replacement therapy
electronic health record